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The new Center for Global Health and Infectious Disease
at Washington University serves as a hub for numerous
initiatives. For example, because urinary tract infections
cause significant suffering and medical care costs worldwide, researchers are working to better understand,
treat and prevent their recurrence. This image shows the
colorfully stained tissue of an infected bladder and its
dark interior cavity, called the lumen. The bladder lining,
light blue, is expelling E. coli bacteria, green, into the
lumen. Proliferating cell nuclei, red, reveal the organ’s
attempt to restore a protective barrier.
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A global search for the underlying roots of disease

B

y decoding the genomes of more
than 1,000 people whose homelands stretch from Africa and Asia
to Europe and the Americas, scientists have
compiled the largest and most detailed catalog yet of human genetic variation.
The 1000 Genomes Project involved some
200 scientists at Washington University School
of Medicine and other institutions. Results
detailing DNA variations of individuals from
14 ethnic groups were published Oct. 31 in the
journal Nature. Eventually, the initiative will
involve 2,500 individuals from 26 populations.
“With this resource, researchers have a
road map to search for the genetic origins of
diseases in populations around the globe,”
says one of the study’s co-principal investigators, Elaine R. Mardis, PhD, co-director of The
Genome Institute at Washington University.
“We estimate that each person carries up to
several hundred rare DNA variants that could
potentially contribute to disease.”
2 Washington University School of Medicine

During the pilot phase of the effort, the
researchers found that most rare variants
differed from one population to another, and
that they developed recently in human evolutionary history, after populations in Europe,
Africa, Asia and the Americas diverged from a
single group. The current study bears this out.
“This information is crucial and will
improve our interpretation of individual
genomes,” says another of the study’s
co-principal investigators, Richard K. Wilson,
PhD, director of The Genome Institute and a
pioneer in cancer genome sequencing.

New data may explain an
individual’s susceptibility
to disease, response to
drugs or reactions to
environmental factors.

All study participants submitted anonymous DNA samples and agreed to have their
genetic data included in an online database.
The researchers first sequenced the entire
genome — all the DNA — of each individual.
To find the rare variants, they sequenced the
small portion of the genome that contains
genes — about 80 times for each participant
to ensure accuracy — and they looked closely
for single letter changes in the DNA sequence
called SNPs (single-nucleotide polymorphisms).
The researchers discovered 38 million SNPs
and numerous structural variations, both of
which can help explain an individual’s susceptibility to disease, response to drugs or reaction
to environmental factors.
“This tremendous resource builds on the
knowledge of the Human Genome Project,”
says co-author George M. Weinstock, PhD,
associate director of The Genome Institute.
“Scientists and, ultimately, patients worldwide
will benefit from the extensive effort to understand the shared features and geographic
diversity of the human genome.”
Winter 2012
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Genetic portraits

At the genetic level, any two people are more than
99 percent alike. But rare variants — those that occur
with a frequency of 1 percent or less in a population
— are thought to contribute to rare diseases as well
as common conditions like cancer and heart disease.

Translational research moves
findings to medical practice
Washington University School of Medicine has received a
$50 million grant to help speed the translation of scientific
discoveries into improvements in human health.
The grant, from the National Institutes of Health (NIH),
supports the school’s Institute of Clinical and Translational
Sciences (ICTS), one of 60 such centers in the United States.
“We’re working to advance clinical and translational
research throughout the university,” says ICTS director
Bradley A. Evanoff, MD, assistant dean for clinical and
translational research. “The ICTS is not built around one
specific disease or clinical specialty. We are charged with
speeding the application of research findings in prevention,
diagnosis and treatment across a wide spectrum of health
conditions and research disciplines.”
The grant is a renewal of a Clinical and Translational
Science Award (CTSA), funded through the new National
Center for Advancing Translational Sciences (NCATS),
which is a part of the NIH.
The Institute of Clinical
Evanoff says the ICTS
will
support Washington
and Translational Sciences
University’s strengths and,
serves as a bridge between
in doing so, help pursue
basic and clinical science.
the goals of the BioMed 21
initiative to encourage crossdisciplinary and translational research. Over the next five
years, the ICTS will increasingly focus on promoting three
areas: translating research in genetics and genomics into
patient care, developing and evaluating new therapeutics,
and improving ways to disseminate and implement research
findings so they become part of regular medical practice.
Other major goals of the ICTS include providing financial
support and training for new investigators in clinical and
translational research, building new research support infrastructure, encouraging collaborations among faculty across
disciplines, and creating pathways for investigators to find
and utilize existing research resources.
Evanoff also emphasizes that the ICTS is a regional
consortium that includes important partnerships with
BJC HealthCare, Barnes-Jewish Hospital, St. Louis Children’s
Hospital, Saint Louis University, the St. Louis College of
Pharmacy, the Goldfarb School of Nursing, and the nursing
schools at the University of Missouri-St. Louis and Southern
Illinois University-Edwardsville.
“Together with our regional and national partners, our
mission is to connect research findings to their eventual
application in improving the health of the public,” Evanoff
says. “That’s the exciting part of translational research.”
outlook.wustl.edu
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Grant to speed discoveries for patients

Listen, talk, read

Andrea Martin, a teacher at CID–
Central Institute for the Deaf, works with children who are deaf or
hard of hearing to help them “listen, talk, read and succeed.” CID
partners with the School of Medicine’s Program in Audiology and
Communication Sciences (PACS) as a training site for its graduate
education programs, which include a Doctor of Audiology (AuD),
a Master of Science in Deaf Education (MSDE), and a Doctor of
Philosophy (PhD), as well as the new minor in Speech and Hearing
Sciences for undergraduates. PACS is part of a consortium of programs
known as CID at Washington University School of Medicine, which
also includes hearing research programs and adult audiology clinics.

Fraser heads Department of Medicine
Victoria J. Fraser, MD, has been named head of the school’s
Department of Medicine. With more than 400 faculty
members, the department is the largest of the School of
Medicine’s departments. It receives more grant funding than
any other research enterprise at the
school and is the largest clinical
service at Barnes-Jewish Hospital.
Fraser, the Adolphus Busch
Professor of Medicine and codirector of the Division of Infectious
Diseases, had been interim head of
the department since August 2010.
“I am honored to get the opportunity to serve in the same position as
some of the key physician-scientists
who built the School of Medicine
into a world leader in research and
clinical services,” Fraser says. “I look Victoria J. Fraser, MD
forward to the challenge of maintaining the department’s
excellence and building upon that foundation as we face
future challenges.”
Fraser also is co-principal investigator of the Washington
University Institute of Clinical and Translational Sciences
and is principal investigator of the research, education,
training and clinical development arm. She also serves as
physician-in-chief at Barnes-Jewish Hospital.
Outlook 3
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With honors
Second-year medical
student Stephen W.
Chi, shown here with
Koong-Nah Chung, PhD,
associate dean for medical
student research, received the
Washington University Summer
Research Prize at the annual student
awards luncheon held in November. Chi, under
the guidance of David C. Beebe, PhD, is studying the proliferation of
corneal epithelial stem cells, which has implications in corneal repair
and transplants. Second-year medical student Nicholas S. Yozamp,
working with Steven L. Brody, MD, also won a summer research prize.

Physical therapy grant funds training

NIH K12 HD055931

The Program in Physical Therapy at Washington University
School of Medicine has received a five-year, $4.6 million
grant to continue an interdisciplinary training program for
occupational and physical therapists that began in 2007.
Michael J. Mueller, PhD, professor of physical therapy, is
principal investigator of the Washington University-based
multicenter grant, called the Comprehensive Opportunities
for Rehabilitation Research Training (CORRT).
Supported by the Eunice Kennedy Shriver National
Institute of Child Health and Human Development of the
National Institutes of Health (NIH), CORRT helps new
physical and occupational therapists acquire the necessary
skills to become independent
The renewed grant helps
researchers. Successful applicants
train with at least two senior
new physical and occupamentors: a physical or occupational
tional therapists acquire the
therapist and another researcher
necessary skills to become
from a different discipline. Twenty
independent researchers.
Washington University faculty from
diverse areas are available to serve
as mentors along with more than 40 other researchers from
partner sites across the country.
“We’re very excited about the program’s progress,” says
Mueller. “So far, six of the 17 scholars have earned individual
NIH grants. We look forward to our scholars’ continued success with the ultimate goal of helping them launch research
that will improve the lives of people with disabilities.”
The new funding allows the program to develop a
communication network, headed by M. Carolyn Baum, PhD,
director of the Program in Occupational Therapy, and add
three new training sites: Boston University, Colorado State
University and the University of Colorado, Denver. Current
sites include Emory University, Johns Hopkins School of
Enjoy interactive elements and added content
Medicine, University of Delaware, University of Iowa and
the University of Pittsburgh.
4 Washington University School of Medicine

Two faculty members elected
to NAS’ Institute of Medicine
Medical science contributions honored
Wayne M. Yokoyama, MD, and Charles F. Zorumski, MD,
have been elected to the Institute of Medicine, a part of
the National Academy of Sciences. The two were among
70 members so honored based on their contributions to
advancing public health, health care and medical science.
Yokoyama is the Sam J. Levin and Audrey Loew Levin
Professor of Research in Arthritis and professor of medicine and of pathology and immunology. In 2007, he became
director of the Medical Scientist Training Program at
Washington University.
Also an investigator of
the Howard Hughes Medical
Institute and a rheumatologist at Barnes-Jewish Hospital,
Yokoyama is known internationally for his research on
the immune system, especially
into the workings of natural
killer (NK) cells. NK cells
monitor the “credentials” of
cells in the body, targeting for
elimination those that lack the
proper identification, such as
tumor cells and those infected Wayne M. Yokoyama, MD
with viruses.
Zorumski is the Samuel B.
Guze Professor of Psychiatry
and Neurobiology and head of
the Department of Psychiatry.
He also serves as psychiatristin-chief at Barnes-Jewish
Hospital and director of the
McDonnell Center for Cellular
and Molecular Neurobiology.
His work focuses on neuron
communication in the brain,
especially in the hippocampus,
and on understanding how
Charles F. Zorumski, MD
neurotransmitters and neuromodulators facilitate learning and memory.
His work studying anesthetic drugs led to the recent
formation of the Taylor Family Institute for Innovative
Psychiatric Research. Under Zorumski’s leadership, the goal
of the institute is to understand the roles of natural and
synthetic neurosteroid molecules in psychiatric illnesses like
depression and schizophrenia, and to identify neurosteroid
targets that could lead to new therapies.
Winter 2012
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A study led
by Roberta G. Pineda, PhD, research
assistant professor of occupational
therapy and of pediatrics, far left, has
documented developmental differences
between premature babies in the NICU
and full-term babies. Pineda’s work
with premature babies, observed by
students from the school’s Program
in Occupational Therapy, points
to intervention in the NICU to
improve preemies’ long-term
outcomes. Terrie E. Inder, MD,
professor of pediatrics, is
the principal investigator
for the study, which is
funded by the National
Institutes of Health (NIH).
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The best start

pediatrics

Do asthma steroids measure up?

outlook.wustl.edu

albuterol, a fast-acting drug for relief of acute
asthma symptoms, and oral corticosteroids
as needed for asthma symptoms.
The researchers followed 943 participants
at regular intervals until they reached adult
height (females, age 18; males, age 20). The
mean adult height was about one-half inch,
or 1.2 centimeters, shorter in the group that
received budesonide than in the patients
who received nedocromil or a placebo. The
patients who experienced the slower growth
were primarily between five to 11 years old
when they began using budesonide.
The slower growth took place only in the
first two years of the four-year study. As the
study progressed, the children who took the
budesonide remained one-half inch shorter
through adulthood than those who did not.
“This was surprising because in previous
studies, we found that the slower growth was
temporary, not affecting adult height,” says
Strunk, who treats children with asthma at
St. Louis Children’s Hospital. “But none of
those studies followed patients from the

Pediatric asthma specialists at St. Louis Children’s Hospital
keep a close watch on the growth of their patients.
time they entered the study until they had
reached adult height.”
Strunk, the CAMP study chair, says
researchers considered other factors that also
might have contributed to the slower growth
rate, but found these to have no impact.
“If a child is not growing as they should,
we may reduce their steroid dose,” he says.
“But that half-inch of lowered adult height
must be balanced against the well-established benefit of inhaled corticosteroids in
controlling persistent asthma.”
Outlook 5
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C

hildren who use inhaled steroids
for asthma end up slightly shorter
at their full adult height than
children who don’t use the drugs, new results
from a comprehensive asthma study show.
The findings were published online on
Sept. 3, 2012, in the New England Journal
of Medicine. The study’s senior author is
Robert C. Strunk, MD, the Donald Strominger
Professor of Pediatrics.
The study involved more than 1,000
children ages five to 12 who were treated
for mild to moderate asthma as part of the
Childhood Asthma Management Program
(CAMP) clinical trial. The children received
treatment for more than four years at eight
centers, including Washington University
School of Medicine.
Study participants were divided into three
groups: one received twice-daily budesonide,
an inhaled corticosteroid medication; a second group received nedocromil, an inhaled
non-steroid medication; and a third group
received a placebo. All children received

pulse

NFL funds brain concussion study
Neurologists at the School of Medicine have received funding
to study the brain following repeat concussions. The project is
one of 15 nationally selected by NFL Charities, the charitable
foundation of the National Football League Owners.
“We are excited about investigating what happens to the
brain’s wiring system following concussions,” says David L.
Brody, MD, PhD, associate professor of neurology. “We’re
honored that the NFL has given us the opportunity to
contribute to a greater understanding of the aftereffects of
repetitive concussive brain injuries. We hope that this will
lead to better ways to prevent and
treat them.”
The NFL-funded project will use a
type of magnetic resonance imaging
(MRI) to measure damage in the brain’s
white matter after repetitive concussive
brain injury. The white matter consists
primarily of long nerve cell extensions
called axons that serve as the brain’s
wiring system.
Last year, Brody’s group published a paper in the New
England Journal of Medicine describing how they used the
same MRI method to analyze the wiring in the brains of U.S.
military personnel who had suffered blast-related injuries.
“There are a number of differences between blast-related
injuries and repetitive sports-related concussions,” Brody
says. “So it will be critical to validate the MRI method in
a model of repetitive concussion to help us understand the
meaning of any findings we may observe.”
6 Washington University School of Medicine
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Visionary research Andrew Yoo, PhD, Robert W.
Gereau IV, PhD, and Michael R. Bruchas, PhD, have been awarded
grants from the National Institutes of Health (NIH) Common Fund to
pursue innovative ideas that have the potential to transform science
and improve public health. The awards are part of a High Risk-High
Reward program that provides opportunities for innovative investigators in any area of health research to take risks when the potential
impact in biomedical and behavioral science is high. To learn more
about their individual research, visit outlook.wustl.edu.

Researchers at Washington University School of Medicine
have received a $9 million grant to investigate blood-clotting
disorders. From heart attacks and strokes to uncontrolled
bleeding, clotting disorders cause more deaths each year in
the United States than all types of cancer combined.
“Blood clots in veins and arteries remain one of the great
killers,” says principal investigator J. Evan Sadler, MD,
PhD, professor of medicine and chief of the Division of
Hematology. “The goal of this grant is to shorten the time
between a new discovery in blood clotting or bleeding disorders and the application of that knowledge to help patients.”
Washington University is one of only five universities
across the country receiving funding from the National
Heart, Lung, and Blood Institute (NHLBI) to support a
new Translational Research Center in Thrombotic and
Hemostatic Disorders.
At Washington University, researchers are focusing on
five projects that look at bleeding disorders, including some
that are rare, and clot
formation in both large
and small blood vessels.
Sadler emphasizes the
value of studying uncommon bleeding disorders.
“Many discoveries in
this field have been made
by the careful investigation of unique patients
with inherited disorders
that are quite rare,”
Sadler says. “But the
knowledge gained from
studying those patients
has provided a foothold
into understanding
thrombosis or bleeding
Strands of a protein called von Willebrand
in humans generally.”
Factor (orange) play a key role in blood
The five initial
clotting. Secreted by cells lining the blood
projects will be led by
vessels, the strands capture platelets and
Sadler, John P. Atkinson,
initiate the formation of blood clots.
MD, the Samuel Grant
Professor of Medicine, Enrico Di Cera, MD, professor
and chairman of biochemistry at Saint Louis University,
George J. Broze, MD, professor of medicine, and Samuel A.
Wickline, MD, professor of medicine.
The grant also supports several core resources, such as a
tissue banking core, and an educational component.

Blood

Research, core resources to benefit
robert boston

robert boston

New center to study bleeding
disorders and clot formation

robert boston

Posted! Attendance was high at
the seventh annual Research Training
Symposium and Poster Session held at
the School of Medicine’s Farrell Learning
and Teaching Center in October. The
event, which showcases basic, clinical
and translational projects by junior
faculty, fellows, residents and training
program students, also featured keynote
speaker Curtis L. Lowery Jr., MD, director
of Maternal Fetal Medicine and chair and
director of the Department of Obstetrics
and Gynecology at the University of
Arkansas for Medical Sciences. The
symposium is sponsored by the Clinical
Research Training Center of the Institute
of Clinical and Translational Sciences and
the Office of Medical Student Research.

oncology and genetics

Big impacts on smokers’ genes

outlook.wustl.edu

available through clinical trials. Across all
patients, they identified 54 mutated genes
already associated with existing drugs.
“Whether these drugs will actually work
in patients with these DNA alterations
still needs to be studied,” says first author
Ramaswamy Govindan, MD, an oncologist
at the Alvin J. Siteman Cancer Center at
Barnes-Jewish Hospital and Washington
University School of Medicine. “But papers
like this open up the landscape to understand what’s happening. Now we need to
drill deeper to understand how these
mutations cause and promote cancer, and
how they can be targeted for therapy.”
Lung cancer is divided into two types
— small cell and non-small cell, the latter
accounting for about 85 percent of all cases.
Within non-small cell lung cancer are three
further classifications. This current analysis
included two: sixteen patients had adenocarcinoma; one had large-cell carcinoma.
Govindan and Wilson also were involved
in a larger genomic study of 178 patients

Compared to other lung cancer patients, smokers
have 10 times more genetic damage in their tumors.
with the third type, squamous cell carcinoma, recently reported in Nature. That
study was part of The Cancer Genome Atlas
project, a national effort to describe the
genetics of common cancers. According
to Govindan, research is moving toward
clinical trials that will focus on the specific
molecular biology of a patient’s cancer.
Based on this emerging body of genetic
research demonstrating common mutations across disparate cancer types, Wilson
speculates that the field may reach a point
where doctors can label and treat a tumor
based on the genes that are mutated rather
than the affected organ.
Outlook 7
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L

ung cancer patients with a history
of smoking have 10 times more
genetic mutations in their tumors
than those with the disease who have never
smoked, according to a new study from
Washington University School of Medicine.
“None of us were surprised that the
genomes of smokers had more mutations
than the genomes of never-smokers with
lung cancer,” says senior author Richard
K. Wilson, PhD, director of the university’s
Genome Institute. “But it was surprising to
see 10-fold more mutations. It does reinforce the old message — don’t smoke.”
The study appeared online Sept. 13 in
the journal Cell.
Overall, the analysis identified about
3,700 mutations across all 17 patients with
non-small cell lung cancer. Twelve patients
had a history of smoking and five did not.
In each patient who never smoked, the
researchers found at least one mutated
gene that can be targeted with drugs currently on the market for other diseases or

PURPLE CONEFLOWER
YELLOW FOX SEDGE
YELLOW WINGSTEM
CREEK OATS
OAK SEDGE
PALM SEDGE
COLUMBINE
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ANEMONE
JACK-IN-THE-PULPIT
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MISTFLOWER
GARDEN PHLOX
SKULLCAP
GROUNDSEL
MUSCLEWOOD
REDBUD
SWAMP WHITE OAK
GOLDEN CURRANT
WILD GERANIUM
GOLDEN ALEXANDER
FRINGED SEDGE
BOTTLE GENTIAN
OSTRICH FERN
PHLOX PANICULATA
INDIAN PINK
SHINING BLUESTAR
HORNBEAM
PRAIRIE ALUMROOT
AND MORE. ..
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Washington University’s Medical

CENTER
PIECE
Outdoor gathering place
has a growing reputation
A plan for all seasons —
that was the intent behind the Ellen S.
Clark Hope Plaza and its surrounding
landscaping. This expansive and
welcoming green space in the middle of
Washington University Medical Center
has been a point of convergence for the

P H OTO E S S AY BY

School of Medicine community and its

ROBERT BOSTON

visitors for the past two years.
Native greenery — including canopy trees consisting of
swamp white oak, Kentucky coffee tree and willow, with
understory plantings of large drifts of riparian sedges, grasses
and flowering perennials — are alive and in tune with nature,
as evidenced by birds nesting in the area, goldfinches eating the
plentiful coneflower seed heads, and butterflies sipping nectar
from the flowers. Flora that grew throughout the Midwest
centuries ago have returned to reinvigorate the campus.
The Ellen S. Clark Hope Plaza
was designed by artist Maya Lin
with landscape architect Michael
Van Valkenburgh Associates, Inc.
Outlook 9

Relatively common in and of
themselves, what makes the plants
surrounding the fountain unique is
their combination. As a group, they
represent a natural river bottom
plant community. The diversity of
this landscape can be seen nowhere
else in the region at this scale.
FROM LEF T: ostrich fern, purple coneflower,
yellow wingstem, aromatic astor, garden phlox
and creek oats
BACKGROUND: water lilies

10 Washington University School of Medicine
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As part of a larger picture that includes brush
strokes from local history, wildlife, ecology, education
and evolving thoughts about the planned landscape,
these plants belong here — as do the people who come
to enjoy the respite provided by this verdant oasis.

12 Washington University School of Medicine
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to heroin
C R E AT E D I N T H E L AT E 1 9 T H C E N T U R Y, H E R O I N
— an opiate analgesic first formulated to treat severe pain —
has had a long and not-so-pristine existence. As other drugs go
in and out of fashion, heroin remains a staple of the illegal drug
trade, a favorite of users for its easy availability and the euphoric
“high” it produces.

How fixing one
drug problem
inadvertently
boosted another
BY JIM DRYDEN

The continuing “popularity” of heroin has never been
lost on Theodore J. Cicero, PhD, who has been studying
the drug and its abuse for the past four decades.
But even he admits surprise at the latest wrinkle in
the heroin game: A reformulation of OxyContin —
a prescription painkiller widely abused in the 1990s —
has made it harder for users to alter that drug for

inhalation or injection. As a result, they are switching from
OxyContin to other drugs, including heroin.
And although only about 10 percent of former OxyContin users
have turned to heroin (the other 90 percent use other opiates,
such as Vicodin or fentanyl), that statistic may be misleading.
“It sounds like a small number,” says Cicero, “but it’s a huge
number relative to heroin users in this country. What’s more,
we’re now seeing a migration of heroin and other dangerous
drugs from the inner cities to the suburbs and rural areas.”
14 Washington University School of Medicine
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Cicero’s research into heroin began in the 1970s,

when he and colleagues were studying the drug’s
effects using animal models. They found — and
later confirmed in human studies — that morphine (to which heroin converts in the brain),
depresses testosterone, the male sex hormone,
leading to hypogonadism, a now well-recognized
side effect of chronic opioid abuse.
So for 20 years, the investigators dealt mainly
with young men from urban minority populations
in their study of heroin,
which at that time was
essentially the only opiate available for purchase
on the street. In the
1990s, with the emerging
popularity of OxyContin,
in suburbs
known as “hillbilly
and rural a
reas
heroin” by its rural and
— THEODORE J. CICERO, MD
suburban users, heroin
suddenly had a director competitor.
Now Oxycontin’s formula change has left users
in need of a substitute, and heroin has once again
made tremendous inroads.
And although heroin abuse is a complicated
issue, Cicero is frustrated by the government’s
focus only on shutting down the supply of illegal
drugs. Instead, he is more interested in the “why”
of drug use, and current studies in his laboratory
are examining risk factors for heroin and other
opioid abuse to decrease the demand side of the
supply-and-demand economic model.
“This trend toward increases in heroin use is
Examining samples in the
important,” says Cicero. “As users switch to
lab: Neuropharmacologist
heroin, overdoses may become more common.
Theodore J. Cicero, PhD, and
We want to get the word out to physicians,
senior research coordinator
regulatory officials and the public.”
Matthew S. Ellis, MPE

we ’re now seeing rep

ort s fr om

across the country of large

quantities of heroin
appearing

Robert Boston

For the past three years, Cicero and
colleagues have collected information from
patients entering treatment for drug abuse.
More than 2,500 patients from 150 treatment centers in 39 states have answered survey
questions about their drug use, with a focus on the
reformulation of OxyContin. Results from those
surveys were published in the July 12, 2012 issue
of the New England Journal of Medicine.
The widely prescribed pain-killing drug originally was thought to be part of the solution to the
abuse of opioid drugs because OxyContin (the
brand name for the generic drug oxycodone) was
designed to be released into the system slowly,
thus not contributing to an immediate “high.”
But creative drug abusers quickly figured out
how to evade that mechanism by crushing the pills
and inhaling the powder, or by dissolving the pills
in water and injecting the solution, thereby getting
an immediate rush as large amounts of the drug
entered the system all at once.
Unlike “street” heroin, which varies in purity
and is often laced with dangerous fillers by drug
dealers, OxyContin came as advertised: Users
knew the exact dosage they were getting and, in its
slow-release form, that was a lot — as much as 15
to 20 times more oxycodone than what comprised
the normal immediate-release capsules.
In addition, from a psychological standpoint,
many OxyContin abusers felt it wasn’t such a bad
thing; after all, it was legal with a prescription and
carried none of the stigma of heroin usage.
To combat these issues, the drug’s manufacturer introduced a new formulation of OxyContin
in 2010. The new pills were much more difficult to
crush and dissolved more slowly. The idea, according to Cicero, was to make the drug less attractive
to illicit users who wanted to experience an immediate high. And it worked — sort of.
“Our data show that OxyContin use by inhalation or intravenous administration has dropped
significantly since the abuse-deterrent formulation
came onto the market,” says Cicero, professor of
neuropharmacology in psychiatry. “In that sense,
the new formulation was very successful.”
However, although many users stopped using
OxyContin, they didn’t stop using drugs.
“The most unexpected, and probably detrimental, effect of the new formulation was that it
contributed to a huge surge in the use of heroin,
which is like OxyContin in that it also is inhaled
or injected,” Cicero says. “We’re now seeing
reports from across the country of large quantities
of heroin appearing in suburbs and rural areas.”
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Promise the

FUTURE
New hope for tomorrow — designed, built,
and tested one piece at a time. B Y H o l ly E d m i s t o n

ROBOTIC
A R M can be
controlled
directly by
the brain
A D V A N C E D BR A I N
R E T R AC T O R
for safer surgeries

Digital image by Eric Young

BONE GROWTH
S T I MU L AT O R
to speed healing
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I M A G I N A T I O N may seem like a childhood dream,
a mere glimpse of a gossamer vision of some wished-for reality.
But neurosurgeon Eric C. Leuthardt, MD, defines
imagination somewhat differently. For him, imagination is
where reality begins.
Leuthardt, associate professor of neurological surgery
and neurobiology, is the director of the Center for Innovation
in Neuroscience and Technology (CINT), a cross-disciplinary
group within the Department of Neurosurgery that brings
together experts from across Washington University to foster
A CINT team meets regularly to discuss testing results.
creativity and innovation.
That effort has proved fruitful. In the three years since
its inception, CINT has engaged 32 clinical and non-clinical
inventors, resulting in 47 ideas, 16 fellowships and 12 patents —
N O N - I N VA S I V E
for which seven have been licensed to industry.
BR A I N S I G N A L S
Cross-connections — validating the science, demonstrating
facilitate
stroke rehab
that a new medical procedure brings value to patients, accessing
new markets in industry, and resonating with the zeitgeist of
humanity — are vital to the success of any invention.
The CINT provides an effective, ethical framework for these
considerations. But for Leuthardt, everything circles back to
envisioning the future.
“Anything that can be imagined can be done,” he asserts.
“The challenge is to imagine how the world can be different,
and then the world figures out a way to make that happen.”
CONTINUED ON PAGE 20

»

BR A I N - CO N T R O L L E D
HAND ORTHOTICS
to speed stroke recovery
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ideas
Effective Building
into medical
Creativity breakthroughs

N

ever has there been such potential to improve
human health through technological innovation.
However, financing, regulations and the need for
broad expertise makes innovation challenging. The Center
for Innovation in Neuroscience and Technology (CINT)
devises collaborative strategies for navigating the journey
from an “Aha! moment” to a new medical technology.

generation

INFORMATION GRAPHIC BY ERIC YOUNG

Experts in medicine, science,
engineering, law, business and
finance convene at “Invention
Sessions” where they discuss clinical
needs, emerging technologies and
market opportunities. These aren’t
classes, but participants do get
“homework”: assess the clinical
problem, the novelty and feasibility of
the idea, and the size of its potential
market. The experts reconvene to
refine various concepts, rank them
in order of their potential, and
recommend them for the next phase.

evaluation

validation

translation

Each idea earns a chance to shine
in the spotlight under the scrutiny
of the CINT’s executive committee
as it considers a range of real-world
questions. Does research support
the merits of an idea? Is it really
better than any new or existing
technologies? Is it novel enough for
licensing? Would the market adopt
it? How long, difficult and costly
will the regulatory approval be?
Some ideas are rejected; some are
modified. The top ideas are assigned
to innovation teams.

Innovation fellowship teams,
composed of faculty and students
from neurosurgery and engineering,
develop rough concepts into working
prototypes. Teams establish clinical
and medical specifications, draft
engineering designs, and create
working physical prototypes.
Along the way, physicians learn
about mechanical, legal and
industry-related
issues; engineers gain
an understanding of
clinical nuance.

CINT embodies a transformation
of academic culture, fostering
experimental creativity,
entrepreneurial activity and
collaborative enterprise. Thinking
“outside the box “ will deliver more
advanced biomedical technology
in the foreseeable future.

Perilous valley

$.1 $10

CLINICAL TRIALS

$100
PRODUCT

A “Death Valley” gap between
public and private support for
costly device research discourages
inventors. CINT bridges this gap
by working with investors to
target worthy ideas — speeding
the process, improving results
and controlling costs.

Private $

prototype

Public $

MILLIONS OF $

Electrodes monitor brain
activity (red) as a patient
responds during “awake”
surgery. By comparison,
new technology will allow
neurosurgeons to monitor
the brain while a patient is
under general anesthesia,
providing a more efficient
and safer way to identify
and preserve critical areas
of the brain.

The past 100 years has created an impressive track record of
how imagining can lead to new realities, says Leuthardt, who
also is an associate professor of biomedical engineering and
of mechanical engineering and materials science.
From commonly used technologies such as instant
messaging and Skype to more esoteric military applications
such as Lockheed Martin’s HULC (human universal load
carrier), imagination is the catalyst of invention.
At the CINT, Leuthardt and colleagues focus on creating
new technology to serve neurosurgery. By formalizing relationships among the School of Medicine’s Department of
Neurosurgery, the School of Engineering and the Office of
Technology Management, collaborators at the center hope to
foster creativity and streamline the process of scientific and
technical innovation and real-world application.
Much of the work being done at the CINT is focused on
technologies that can impact care of patients with neurologic
disease. This ranges from the creation of specialized devices
to the more fundamental fields of neuroprosthetics, motor
physiology, speech physiology, epilepsy and stroke rehabilitation. The technologies that have emerged have encompassed
a broad range, including implantable sensors to treat hydrocephalus, novel coatings of orthopedic hardware to facilitate
bone growth, and engineering solutions for stroke.
The idea of a brain-computer interface has been a flagship technology and scientific endeavor of the CINT. Indeed,
many of the inventions developed or under consideration are
related to issues of restoration, enabling people with spinal
cord injuries or who have had a stroke to regain function.
“That’s where we begin, but it’s not where we end,” says
Leuthardt. “As a physician, it’s critical to restore function to
people with motor disabilities — that’s absolutely vital. But
that is Chapter 1 of how we see ourselves, what we think our
limitations are. Maybe our ability to interact with the world
no longer stops with our fingertips and bodies, in a real way.”
Fundamentally, Leuthardt hopes to change how humans
interact with machines. Although that might sound like
science fiction, neuroprosthetics — devices linked to the
brain that allow patients to move a robotic arm or a cursor
on a screen simply by thinking about doing so — already
exist. According to Leuthardt, this type of technology will
one day be as commonplace as the video games of today.
“My job is to make it boring,” he says. “We may get
excited about the new iPhone 5, but we don’t get excited by
20 Washington University School of Medicine

our DVD players anymore. Similarly, neuroprosthetics, body
modulation and cognitive capability will one day no longer
inspire awe at the magnitude of the technical accomplishment; they will just be a part of everyday life.”
Another key area of study at the CINT is brain mapping.
Leuthardt and his colleagues are developing advanced techniques to locate and preserve critical areas of brain function.
During any neurological surgery, a key concern is not
doing any harm to the brain while fixing a problem, such as
operating on tumors or areas affected by epilepsy. Currently,
neurosurgeons are able to watch the brain “light up” in real
time during surgery as participants perform tasks such as
talking or moving their hands. However, this process occurs
during “awake” surgeries, something Leuthardt would like
to change. New technology in development will allow neurosurgeons to assess critical brain areas — such as those
devoted to speech and motor function — by monitoring the
specific electrical signatures of various brain networks while
the patient is anesthetized.
This type of breakthrough, which benefits patients by
removing a risk for serious injury, is an example of the type
of inventiveness the CINT hopes to foster. By providing
an institutional structure that brings together people from
diverse backgrounds — medicine, engineering, computer
science, physics, chemistry, mathematics, nanotechnology,
law and business — the CINT promotes collaboration,
allowing innovation teams to generate ideas that none of the
individuals would have been able to create by themselves.
“The world’s become a more complex place,” Leuthardt
explains. “All of these fields have become very subspecialized.
The benefit is that it gives us expertise in that subspecialty,
but it’s also a worldview that can stymie creativity.”
However, he says, if a neurosurgeon and an engineer sit
down to talk, it’s likely the interaction will lead to non-linear, unexpected conclusions. A physician may learn about an
existing technology — something that is very exciting to the
engineer — that would solve a particular medical problem.
“Eric has been successful in creating a wonderful
collaborative research environment within the Department
of Neurosurgery,” says Ralph G. Dacey Jr., the Henry G.
and Edith R. Schwartz Professor and head of neurological
surgery. “The Center for Innovation in Neuroscience and
Technology has facilitated the development of several breakthrough neuromedical technologies.”
Finally, Leuthardt emphasizes that the academic and
medical cultures can be inhospitable to creativity in that
they often do not allow for trial-and-error thinking. In the
creative process, he asserts, it is acceptable, and perhaps even
desirable, to make and learn from mistakes.
“Education and expertise can be limiting,” says Leuthardt.
“We need to be humble about our knowledge so that we can
learn from other people. Innovation, more than ever, comes
out of good relationships with other people.”
Winter 2012

Pitch
Perfect
Introducing good people
and their great ideas

Ray Marklin

By Stephanie Stemmler
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120

Robert Boston

SECONDS

No notes, no props, no polished PowerPoint presentation.
Just two minutes — 120 seconds — of passion and persuasion.
That’s the idea behind IdeaBounce, a campuswide initiative founded in 2003 to support student,
faculty and community interest in commercial,
social, global, technological, legal, artistic and
intellectual entrepreneurship.
IdeaBounce is the brainchild of Washington
University’s Skandalaris Center for Entrepreneurial
Studies. This past October, for the first time, an
IdeaBounce was held at the School of Medicine.
“The time went so fast, and you’re so nervous,”
says Dana M. Watt, a graduate student in anatomy
and neurobiology in the Division of Biology and
Biomedical Sciences. “But I think the judges liked
my idea, and maybe someone will help me take it
to the next level.”
They did. Watt and four others among the 13
people who made pitches were named the event’s
five winners (see WINNING PITCHES, page 23).
As a reward, the winners each received a check
for $50 and the opportunity to spend one-on-one
time with the judges at a dinner after the event.
Credit for bringing the IdeaBounce competition
to the School of Medicine goes to members of the
BioEntrepreneurship Core (BEC), a group of the
school’s graduate and medical students, postdoctoral researchers and faculty who share an
interest in entrepreneurship.

“The university is working hard at emphasizing entrepreneurship,” says Hugh Bender, a
fourth-year doctoral student in developmental,
regenerative and stem cell biology and president
of the BEC. “On the medical school campus, the
National Institutes of Health invests millions of
dollars in research. But what’s the output of that?
“In academia, it’s typically peer-reviewed,
published papers,” he says. “A lot of that research
could also be commercialized; ideas are getting
lost because we don’t think in terms of intellectual
and translational property. We want to focus on
the fact that researchers are creating value, which
should be recognized beyond publications alone.”
Started in 2004, the BEC now boasts a mailing
list of more than 300. The group fosters conversations and idea-sharing through a series of events
throughout the year, including panel presentations
by community entrepreneurs and Washington
University faculty and staff.
The BEC also holds casual morning coffee
lectures and get-togethers, all with the goal of
creating interest in entrepreneurship.
“The BEC represents an opportunity to network
and meet different people in industry,” says Rachael
A. Hansel, a postdoctoral researcher in radiation
oncology. “As a student or postdoc, you are highly
focused on science and that millimeter slice of the
world. I’m looking for jobs, so here you can meet
creative people, bounce ideas and open up your
view of the world and your career possibilities.”
The BEC is a “cohesive nucleus of energy” that
contributes to the culture of entrepreneurship now
blossoming at the medical school, says Kenneth A.
Harrington, managing director of the university’s
Skandalaris Center for Entrepreneurial Studies.
“You don’t know if an idea is viable until you
act entrepreneurially,” says Harrington. “The
reason IdeaBounce is so important is that it helps
people with ideas meet other people who can help
move their ideas forward. In that process, we
develop the idea-makers into entrepreneurs. Once
they learn that, they have that skill for life.”
IdeaBounce offers participants a “speed-dating”
style of competition in which they have just two
minutes to pitch a creative, innovative idea to a
panel of judges. The medical school’s IdeaBounce
Student leaders of the School of Medicine’s BioEntrepreneurship
Core, clockwise from lower left: Dana M. Watt, secretary;
Hugh Bender, president; Matthew C. Hibberd, vice president;
Sriram Devanathan, vice president; Aswin J. Mathews,
treasurer; and Elizabeth A. Germino, marketing director.
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participants, who could present medical, life
sciences or unrelated ideas, were judged on three
essential criteria: clarity of the idea, the passion of
the presenter, and whether they clearly requested
help. Within 45 minutes after IdeaBounce started,
the judges had identified the top five competitors.
“I thought all of the ideas were good,” says
judge Pete Peters, executive director of Innovate
Venture Mentoring Service, a local organization
that provides free, team-based mentoring of new
ventures by business and entrepreneurial leaders.
Peters, who teaches an annual course, Origins of
Bioentrepreneurship, at the medical school, says
becoming an entrepreneur is a learned skill.
“We really need to foster this spirit of entrepreneurship,” he says, “so that people feel comfortable about pursuing ideas and creating a viable
business or product. There are so many resources
at Washington University and around St. Louis
that can help people bring an idea to reality.”
The university already has delved into large-scale
bioentrepreneurial collaboration around St. Louis.
It is a founding member, along with other area universities, of the Center of Research, Technology
and Entrepreneurial Exchange (CORTEX), which
strives to establish the region as an international biosciences powerhouse. In another effort, BioSTL, the
university — with BJC HealthCare and the St. Louis

WINNING PITCHES
IDEA
A new spirometer design

PRESENTER
Andrew J. Brimer, graduate
student in engineering

PITCH
Spirometers measure lung
function, but are expensive,
ranging from several hundred
to thousands of dollars each.
A new, award-winning prototype would cut the production
cost to less than $10.

NEEDS
Mentors, investors, product
development
outlook.wustl.edu

IDEA
Using miRNAs (micro RNAs)
to diagnose lung cancer

PRESENTER
Thomas L. Cohen,
postdoctoral research scholar
in genetics

PITCH
By developing an assay using
miRNAs, lung cancer can be
diagnosed more accurately and
cheaply than current methods.

NEEDS
Team members, mentors,
investors, and legal, financial
and accounting advice

Life Sciences Project — is working to
spur bioscience company creation and
drive economic growth.
“Washington University recognizes the need
and opportunity to expand its research culture, to
foster research innovation and entrepreneurship in
addition to knowledge creation and publication,”
says Evan D. Kharasch, MD, PhD, vice chancellor
for research. “Turning research discoveries into
products and services, so that the public can benefit from our research, is a major institutional goal.”
The BEC is aggressively expanding its presence,
co-hosting interdisciplinary discussions on entrepreneurial topics with Washington University’s
other schools, such as law and business.
“It’s a culture that is shifting toward innovation
and bringing ideas to a practical endpoint,” says
Elizabeth A. Germino, an MD/PhD student in
the university’s Medical Scientist Training
Program. “In medicine and science, you need
collaborations and expertise. One of the strengths
here is the collaborative atmosphere, but, as
students, we’re so focused on what we need to do
to learn our jobs that we may miss essential skills,
such as how to clearly present an idea, pursue it,
and ask for help and resources. The BEC is a
way to learn that from like-minded people.
IdeaBounce makes it fun.”

Students met at a recent
coffee lecture to talk with
Kenneth A. Harrington,
managing director of the
university’s Skandalaris Center
for Entrepreneurial Studies.

Promising ideas from the School of Medicine’s IdeaBounce
IDEA
Mobile drug database app

PRESENTER
Paul G. Gamble, first-year
medical student

PITCH
A mobile app will enable
patients to determine out-ofpocket costs for various drugs
and then identify comparable
cheaper medications. This will
aid in making value-based
treatment decisions.

NEEDS
Mentors, legal advice,
advisors, investors

IDEA
Genotyping to determine
compatibility on dating website

PRESENTER
Masatoshi Kaneko, graduate
student in biomedical
engineering and business

PITCH
Adding geno-typing could
enhance a suitable match
based on intelligence and
personality in addition to
subjective preferences.

NEEDS
Mentors, legal advice,
strategic development

IDEA
Online expert database
for scientists

PRESENTER
Dana M. Watt, graduate student
in anatomy and neurobiology

PITCH
To more cost-effectively
allocate limited research dollars,
an online database will share
scientific expertise and
experiments.

NEEDS
Team members, advisors,
IT, legal advice, operations
and management
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Together.
Together, we learn.
Together, we discover.
Together, we create.
Together, we heal.
Together, we innovate.
Together, we lead.
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In the 20th century, we changed the understanding of medicine.
In the 21st century, we are transforming the very meaning of medicine.
The urgent need to discover the causes of the most common diseases and
to apply this knowledge to successful treatments has never been greater.
An aging population in America — and a growing underserved population
worldwide — have pushed traditional health care delivery to a breaking point.
The solutions are complex, and yet for Washington University
School of Medicine, the action is straightforward. Our mission is to lead
in the advancement of human health. We must train the next generation
of medical leaders. We must martial our extraordinary scientific resources
to eliminate entire diseases and find treatments that improve and prolong
lives. And, ultimately, we must take major steps to improve our efficiency
in streamlining health care delivery, reducing unnecessary costs, and
serving populations in need.
Fortunately, our School
of Medicine is one of the few
Advancing human health through the
institutions — anywhere — with
the vision, depth of experience,
Campaign for Washington University
and combined intellect required
to do what can and must be
done to advance human health. Through innovative research, outstanding
clinical care, and the forward-thinking education of tomorrow’s leaders
in medicine, we have achieved international prominence.
Yet, the task is great — so great, in fact, that it is easy for us
to question how an individual can have the ability to make a significant
difference. However, there is no question that every gift matters.

We invite you to be a part of a historic endeavor:
Leading Together — The Campaign for Washington University

outlook.wustl.edu
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Leading Together
A major, multi-year fundraising initiative, Leading
Together: The Campaign for Washington University,
has been announced by Washington University in
St. Louis to build on its strong history and further
evolve the university’s global leadership.
At the School of Medicine, that translates to
leveraging our strengths throughout the university
to develop techniques and treatments necessary to
help ever-greater numbers of people throughout
the world to live better and longer than previously
thought possible.
“From helping our neighbors take control of
their health to providing cures in countries where
people are still dying from easily treatable diseases,
the faculty, students, and alumni of our School
of Medicine will continue to pursue new ways to
save and improve lives,” says Chancellor Mark
S. Wrighton. “With the support of our alumni,
parents, friends, corporations, and foundations,
we can build upon the accomplishments of recent
decades and contribute even more significantly
to our communities, our nation, and the world.”

Medical school campaign priorities

Images PP. 26–33 by Mark Katzman

The campaign’s four themes — preparing the
leaders of tomorrow, advancing human health,
inspiring innovation and entrepreneurship, and
enhancing the quality of life — will be the focus of
School of Medicine efforts during the campaign.
To succeed in each of these areas, fundraising
targets for five priorities have been identified:
n to attract and retain outstanding faculty:
$240 million
n to attract a talented and diverse student
body: $40 million
n to advance the scholarship, research, and
creative potential of students and faculty:
$750 million
n to further strengthen an exceptional
teaching, research, and working environment:
$40 million
n to enhance excellence throughout the school
by increasing unrestricted annual support:
$30 million
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“Our overarching vision is to use our resources
as a top-tier institution to make significant and
lasting contributions to advancing human health,”
says Larry J. Shapiro, MD, executive vice chancellor
for medical affairs and dean. “To meet these challenges, we must gather resources and make broad
changes to integrate our missions and strategically
focus our efforts.”
Winter 2012

The Campaign for Washington University

Groundbreaking scientific discoveries over
the past century have established the School of
Medicine’s reputation as one of the great medical
centers in America and throughout the world.
The depth and breadth of scientific inquiry
addressed by its researchers has a national and
global impact, and its multi-pronged approach
to research holds tremendous promise for rapid
advances in deciphering fundamental causes of
diseases. Ultimately, research conducted at the
School of Medicine is transforming medicine,
leading to better therapies and therapeutics.

Local and global community outreach

Attracting the best students and faculty

Washington University School of Medicine is a
leading center for teaching, research, and patient
care and is well-known for its tremendous innovation in genomics, neuroscience, imaging, infectious
diseases, cardiology, and biomedical engineering,
consistently ranking among the world’s finest
medical institutions.
Yet our potential for even greater leadership
is much stronger than previously imagined, and
we have never been more committed to expanding upon these great strengths. To this end, we
view the School of Medicine’s prospects for the
advancement of medicine to be virtually limitless.
With the generous support of the alumni and
friends who share our aspirations, our ideals, and
our spirit, we can forge a stronger foundation for
the future. Please join us as we educate and inspire
the next generation of outstanding students in our
unwavering determination to make ever-greater
contributions toward improving human health on
a global scale.

For the past 14 years, Washington University
has recruited the top class of entering medical
students in the country, and scholarships are
critical to this success. The School of Medicine’s
Programs in Occupational Therapy, Physical
Therapy, and Audiology and Communication
Sciences rank among the top three programs
in each of their respective fields nationally.
Signature graduate education programs in the
Division of Biology and Biomedical Sciences and
the Medical Scientist Training Program set the
bar for peers. Likewise, residents and fellows at
the school and our affiliated hospitals are among
the best in the world.
Central to our continuing success is one of the
world’s great medical faculties. In an increasingly
competitive environment for engaging the best
academicians, endowed professorships play
an important role in recruiting and retaining
the most important resource of the School of
Medicine: the extraordinary people who lead the
field in teaching and research. Increasing our
number of endowed professorships is essential
to our leadership position in the field.

Recognizing our clinical physicians

Most importantly, School of Medicine physicians
save lives — and directly work to improve the
quality of life for tens of thousands of patients
each year. With its hospital partners on the
Washington University Medical Center campus
— Barnes-Jewish Hospital and St. Louis Children’s
Hospital — the School of Medicine is committed to
providing the greatest level of healing in the world.
From the most fragile infants to individuals with
extremely rare diseases, physicians provide each
patient with medical expertise that is grounded in
the finest training possible. Working together,
medical teams are skilled in innovative techniques
and fully immersed in compassion for humankind.
outlook.wustl.edu

Actively engaged in neighborhood clinics, schools,
and community organizations that promote wellness, the faculty, students, and staff of the School of
Medicine regularly volunteer clinical services in
underserved areas of St. Louis, the United States,
and at a growing number of international locations.
Through these efforts, Washington University has
demonstrated an unwavering commitment to the
discovery of knowledge and the advancement of
medical research and patient care.

Partnering for success

“We believe answering
the great questions in
medicine requires bold
research focused in areas
of high reward. The time
for answers is now. Every
individual can help us
find them. Together, we
will make a difference.”
Larry J. Shapiro, MD
Executive Vice Chancellor for
Medical Affairs and Dean

The following pages summarize key areas in which
support is needed to advance human health:
• Understanding the Brain
• Cancer and Personalized Medicine
• Diabetes, Heart Disease, and Obesity
• Infectious Diseases and Global Health
• The Next Generation
• The Annual Fund

Learn more: medicalalumni.wustl.edu
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Together,
we discover.
Washington University researchers
are committed to studying the
human brain across the life span.
Terrie E. Inder, MD, PhD, studies
neurodevelopmental outcomes of
newborn infants.

Understanding the Brain

T

HE HUM A N BR AIN
remains a critical frontier
in modern-day medicine.
Brain diseases devastate millions
of families through loss of
life, cognitive and emotional
disability, social and financial
instability, and fear. Washington
University is at the forefront of
discovery and treatment in
neuroscience. Our enduring
partnerships with alumni,
friends, and philanthropists
allow us to advance the field,
simultaneously providing
treatment to patients in need
and influencing the healing of
others throughout the world.

Areas of excellence
n The Charles F. and Joanne Knight

Alzheimer’s Disease Research Center
(Knight ADRC) is internationally
known for leadership in the field.
Researchers at the Knight ADRC not
only developed the standard clinical
measure for staging of dementia,
but also established that Alzheimer’s
disease begins damaging the brain
decades before the first appearance
of outward symptoms.
n The Taylor Family Institute for

Innovative Psychiatric Research in
the Department of Psychiatry is
advancing the science underlying
the diagnosis and treatment of
psychiatric illnesses.
n At the Hope Center for Neurological

Disorders, more than 500 scientists
are devoted to discovering fundamental causes of neurological
disorders such as Alzheimer’s and
Parkinson’s diseases, multiple sclerosis,
and amyotrophic lateral sclerosis
(ALS, or Lou Gehrig’s disease).

n With more than 17,000 new cases

of malignant brain tumors diagnosed each year, the Department of
Neurological Surgery is developing
new approaches and clinical trials.
n Scientists and physicians at the

Intellectual and Developmental
Disabilities Research Center provide
the latest research to families of children with developmental disabilities.
n Washington University has been

chosen by the National Institutes of
Health (NIH) to lead a consortium
of research institutions in the
Human Connectome Project, a bold
effort to map the human brain.
n The Washington University

Neurofibromatosis Center in the
Department of Neurology is the
largest and most comprehensive
center of its kind in the world.

Together, we can
n fund clinical trials in Alzheimer’s

disease and advance our leadership
in Alzheimer's and related disorders.
n develop drugs to treat mental illness.
n discover treatments for childhood

disabilities.
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Together,
we lead.
The Alvin J. Siteman Cancer Center,
led by Timothy J. Eberlein, MD,
the Spencer T. and Ann W. Olin
Distinguished Professor, is a
beacon of hope for cancer patients
and their families.

Cancer and Personalized Medicine

A

S A LEADER in
diagnosis, treatment,
and prevention, the
Alvin J. Siteman Cancer Center
at Barnes-Jewish Hospital
and Washington University
School of Medicine is driving
an ever-greater convergence
among oncology, genomics,
imaging, and pathology. Its
interdisciplinary approach
to translating laboratory
findings into comprehensive,
compassionate patient care
will ultimately foster the
development of personalized
medicine for cancer and
other diseases.

outlook.wustl.edu

Areas of excellence
n Led by investigators in the

Department of Medicine’s Division of
Oncology, collaborative and creative
research seeking to uncover causes
and cures for cancer takes place in
nearly all departments and divisions
throughout Washington University
School of Medicine. The division also
has joined with several institutions in
creating a protein atlas.
n The Genome Institute has helped to

define and understand the makeup of
the human genome in myriad ways,
including contributing 25 percent of
the finished sequence to the Human
Genome Project. This effort informs
other research, including successfully
decoding — for the first time in
history — the complete DNA of a
cancer patient by tracing her disease, acute myelogenous leukemia,
to its genetic roots. In sequencing
the patient’s entire genome and the
genome of her leukemia cells, investigators were able to identify the
genetic changes unique to her cancer.
In addition to its hope for saving lives,
this work promises to accelerate the
era of personalized medicine.

n The Department of Radiation

Oncology works with units across
the entire medical enterprise on the
development and implementation of
new cancer treatments. The recent
acquisition of the Midwest's first proton accelerator allows physicians to
target tumors with greater precision
and minimize radiation of vital organs
and tissues surrounding tumors.
n Genomics and Pathology Services

(GPS), a collaborative effort between
the Department of Pathology and
Immunology and the James S.
McDonnell Department of Genetics,
provides expertise in genetic testing
and pathology consultation, including
clinical genomics and next-generation
sequencing.

Together, we can
n develop tests to detect cancer at its

very beginnings and to assess genetic
cancer risk.
n identify and evaluate strategies for

stopping cancer growth or preventing
it altogether.
n lead the nation in research and

treatment of multiple myeloma.
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Together,
we innovate.
Douglas L. Mann, MD, the Tobias and
Hortense Lewin Distinguished Professor
of Cardiovascular Diseases, leads the
university’s participation in a national heartfailure research network sponsored by the
National Institutes of Health (NIH).

Diabetes, Heart Disease, and Obesity

H

EART DISEASE ,
affecting more
than 82 million
Americans, is the leading cause
of death in the United States
for adults. In addition, heart
disease is the leading cause of
complications and death for
two-thirds of the 25 million
people with diabetes in this
country. Obesity plays a major
role in both diseases in adults
and children. Researchers
are tackling these combined
problems by providing clinical
treatment and conducting
scientific studies throughout
the School of Medicine in more
than a dozen multidisciplinary
programs and centers.

Areas of excellence
n At the Diabetic Cardiovascular Disease

Center (DCDC), investigators are working toward a better understanding
of the underlying basis connecting
diabetes and heart disease.
n The School of Medicine is a world-

class center for research, educational,
and clinical care programs in atrial
fibrillation, minimally invasive cardiac
surgery, aortic surgery, ventricularassist devices, and heart transplant.
n Innovative research, along with

successful treatments and education
programs, is changing lives at the
school’s Human Nutrition Center.
n Patient care and research in diabetes

are advancing on multiple fronts:
understanding and treating childhood diabetes by the Department of
Pediatrics, significant advances within
the Department of Medicine’s Division
of Endocrinology, genetic studies
on type 1 diabetes at The Genome
Institute, and research into electric
signaling in tissues at the Center
for the Investigation of Membrane
Excitability Diseases (CIMED).

n The Cardiovascular Division has

emerged as a national leader in
both research and delivery of highquality cardiovascular care to a large
patient population. Faculty members in the division have conducted
groundbreaking research in the area
of dissolving blood clots for acute
myocardial infarction, biomarkers for
cardiac injury, and cardiac imaging.
n The David Goldring Division of

Pediatric Cardiology and its partner,
St. Louis Children’s Hospital, have
been recognized for more than a halfcentury for innovative approaches to
infants and children with congenital
heart disease. This reputation continues today with the division's recognition as a national leader in the area of
heart failure and transplantation.

Together, we can
n partner with start-up companies to

develop drugs for heart disease.
n identify defects that underlie many

of the world’s most important diseases, including heart arrhythmias,
diabetes, and epilepsy.
n identify new therapies for heart and

vascular disease in diabetes.
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Together,
we heal.
Mark J. Manary, MD, the Helene B.
Roberson Professor in Pediatrics,
and colleagues have worked for
nearly two decades to reduce
childhood malnutrition.

Infectious Diseases and Global Health

I

MPROVING GLOBAL
HEALTH is among
the world’s most pressing
challenges, and infectious
diseases research has become
one of the largest areas of
concentration within the
School of Medicine. As new
diseases appear, there is an
ever-greater risk of rapid
transmission and spread of
infection. By traveling to
foreign countries to provide
basic health care or by
offering programs in St. Louis
aimed at preventing sexually
transmitted diseases, our
faculty, students, and staff
are dedicated to making
a difference — locally,
nationally, and globally.

Areas of excellence
n Children are disproportionately

affected by infectious diseases, as
well as by malnutrition. In an effort
to cost-effectively reduce the
malnutrition rate and reverse the
cycle of poor health standards and
lower educational achievements
associated with it, School of Medicine
researchers have developed ready-touse therapeutic foods (RUTFs) that
can be locally manufactured, easily
stored without refrigeration, and
successfully used to ensure proper
nutrition for children.
n The study of the human microbiome

promises to provide a better road
map for investigating what goes
awry in diseases thought to have
microbial links and determining why
the dangerous pathogens residing
within us do not always cause lifethreatening illnesses.
n Washington University has been

selected by the federal Centers for
Disease Control and Prevention to
develop and test new approaches
for reducing health care-associated
infections.

n With support from the Bill and

Melinda Gates Foundation, researchers hope to reduce suffering caused
by two tropical diseases: onchocerciasis (river blindness) and lymphatic
filariasis (elephantiasis). By optimizing
simple and cost-effective treatments
already being used to help hundreds
of millions of people, the researchers
seek to provide treatment for many
neglected tropical diseases.
n Washington University’s scope of

work in this broad field includes
patient safety, reduction of hospitalacquired infection incidence rates,
community outreach, and the
establishment of a Midwest Regional
Center of Excellence for Biodefense
and Emerging Infectious Diseases
Research.

Together, we can
n effectively prevent and treat infectious

diseases of the urinary and reproductive tracts to alleviate suffering of
women and children worldwide.
n recognize commonalities among

diseases and, where possible, apply
effective solutions broadly.
n explain diseases not yet known to be

related to infection.
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Together,
we learn.
Teaching and inspiring: David J.
Murray, MD, the Carol B. and Jerome
T. Loeb Professor of Anesthesiology,
helps students develop good
judgment and problem-solving
diagnostic skills in the Howard and
Joyce Wood Simulation Center.

The Next Generation

I

N M E D I C I N E,
knowledge, experience,
and inspiration is passed
from one generation to the
next in a grand continuum.
Washington University is
committed to providing its
students with a rigorous
foundation in science,
advancing the tools needed
to diagnose and treat patients,
and developing the ethical
basis for making critical
decisions in a rapidly changing
health care environment.
Attracting the best students
and faculty, with the support of
alumni and friends, represents
a partnership for the future.
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Areas of excellence
n To secure the future of our leader-

ship in medical education, it is
imperative to increase the number of
endowed professorships for clinical
and basic science faculty, as well as
professorships for preceptors, those
clinicians who provide hands-on
training to students. An endowed
professorship is often a crucial factor
in an individual’s decision to join the
School of Medicine faculty. These
professorships — which provide
support for salary, benefits, and
research needs — are central to
retaining our most promising faculty
and recruiting stellar outside leaders.
n We continue to seek support for

scholarships to address the cost of
education, reduce debt upon graduation, and recruit the best students.
Medical, occupational therapy, physical therapy, and audiology students
have been the primary beneficiaries
of these scholarships; we are extending our efforts to include students
in the Medical Scientist Training
Program and the Division of Biology
and Biomedical Sciences.

n The partnerships our faculty and

students form with our generous
donors are often warm and enduring.
Endowed professorships can serve as
the foundation for lifelong collaboration between faculty and donors in
the advancement of medicine. The
joy of providing a student scholarship,
meeting the student who receives
it, learning about the student’s aspirations, and knowing that one has
played an important role in shaping
the future of medicine can be very
rewarding for donors. For students,
this relationship often inspires them
to make a commitment to continue
the tradition of philanthropic support
when they are positioned to do so.

Together, we can
n recruit and empower the brightest

faculty and most gifted and creative
graduate students.
n advance our leadership in both

innovative learning methods and
in adapting teaching resources to
meet the changes in medical
knowledge and practice.
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Together,
we advance.
Outstanding teacher and
mentor Jeffrey I. Gordon,
MD, the Dr. Robert J. Glaser
Distinguished University
Professor, with trainees in
his laboratory.

The Annual Fund

T

HE ANNUAL FU ND
provides essential
support for scholarships,
seed funding for initiatives that
sustain intellectual vitality, and
resources to respond to new
opportunities and challenges.
Unrestricted annual giving
empowers the leaders of the
School of Medicine to support
its highest priorities, allowing
the university to maintain its
margin of excellence. Every
gift matters; growing our
Annual Fund participation
has never been more critical.

Areas of excellence
n In recent years, reunion class giving

has become increasingly important.
Each year, class gifts to the Annual
Fund provide either fully endowed
scholarships or annually funded
scholarships, honoring the philanthropy of each class gift. Thus far,
23 alumni classes have endowed
scholarships benefitting 231 students.
n Annual Fund gifts from medical

student and house staff alumni
are divided among scholarships,
student programs, alumni endowed
professorships, and other high
priorities of the dean.
n School of Medicine faculty are among

the most committed supporters. Since
2010, current and former faculty have
provided nearly 40 annual scholarships,
demonstrating their commitment to
our students and, most significantly,
to addressing the complexity and cost
of a comprehensive 21st-century
medical education.

n Many former house staff and fellows

support the Annual Fund within the
departments and divisions in which
they trained. Their generosity funds
resident education, research, training,
and special projects.
n The local community benefits from

a wide range of student-initiated
projects. More than 40 of these have
been funded with help of unrestricted
annual gifts.
n The school’s Programs in Physical

Therapy, Occupational Therapy,
and Audiology and Communication
Sciences also benefit from gifts to the
Annual Fund. Most gifts are directed
to student support.

Together, we can
n support the eight out of 10 medical

students who need financial
assistance.
n support student programs that

benefit the community.
n provide alumni endowed professorships.
n provide key resources throughout

the School of Medicine.
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classnotes
1940 s

1980 s

Stanley Kahn, MD 43
Kahn spends time reading, practicing
the piano, and enjoying his two
grandchildren.

Priscilla Bade, MD 87
Bade is a professor of internal medicine
at Sanford School of Medicine at the
University of South Dakota and medical
director of both the Hospice of the Hills
and Golden Living Bella Vista in
Rapid City SD. She coordinates an
interdisciplinary palliative care course
for medical and nursing students and was
a finalist for Medical Director of the Year
from Golden Living District 4.

1950 s
James Dunlevy, MD 51
Dunlevy is living in the Chippewa
National Forest on the shores of a huge
glacier lake in northern Minnesota with
his wife, Allie (Phelps) Dunlevy, NU 50.
Their “neighbors” include deer, loons,
geese, timber wolves, beavers, birds,
ducks and lots of fish.
John Denman, MD 52
Denman enjoys playing the clarinet in
a dixie/big band. He also plays golf
and tennis. He formally retired from
medicine in 2011.
John Finch, MD 59
Finch’s interests include photography,
traveling, reading, fishing and family.

1960 s
David Nelson, MD 63
Nelson is enjoying his retirement in
Hilton Head SC and is looking forward
to his 50th reunion.
Albert Wermuth Jr., MD 67
Wermuth retired from active practice
in 2009.

1970 s
Robin Bernhoft, MD 76
Bernhoft retrained in environmental
medicine and is enjoying practicing
“psychological” medicine.
Alice Ackerman, MD 79
Ackerman has become active in social
media, keeping a children’s health care
blog at www.carilionclinic.org/blogs/
ackerman. She has two young grandsons.

34 Washington University School of Medicine

1990 s
Cheryl Whitaker, MD 93
Whitaker was appointed chief medical
officer of Merge Healthcare. She also was
appointed by Governor Pat Quinn to the
board of directors of the Illinois Health
Information Exchange Authority.
Thomas Allen, MD 97
Allen is an assistant professor of pediatrics
at the University of Central Florida/
Nemours Children’s Hospital. His pastimes
include traveling and skiing in Austria.

2000 s
Edward Miner, MD 02
Miner is an interventional cardiologist
at Utah Heart Clinic in Salt Lake City UT.
He has five children and enjoys playing
basketball, skiing and teaching his
children. Though he no longer lives in
St. Louis, he is still a Cardinals fan.

In Memory
Bernard Adler, MD 37
Adler died April 14, 2011. He was 97.
Jerome Madden, DE 42
Madden died April 19, 2011. He is
survived by five children, five grandchildren and many friends.
John Martz, MD 42, HS 47
Martz, 95, died April 6, 2012. He served
as a captain in the U.S. Army Medical
Corps treating the wounded on the front

lines in World War II. He retired in 1985
after 37 years as a pediatrician and as an
associate professor of clinical pediatrics at
Washington University School of Medicine.
Virginia Peden, MD 47
Peden died May 28, 2011. She is survived
by a brother, four children and six
grandchildren.
Thomas Zaydon Sr., HS
Zaydon died Jan. 12, 2012. He was
former chief of plastic surgery at Miami
Heart Institute, St. Francis, Mount Sinai and
Mercy Hospital and received numerous
civic, religious and professional awards.
He is survived by eight children, seven
grandchildren, numerous nieces and
nephews, and many other close family
members, friends and colleagues.
Noah Susman, LA 48, MD 52, HS 55
Susman, who died March 1, 2012, was
professor emeritus of clinical radiology at
Washington University School of Medicine
and a former chief of radiology at Jewish
Hospital of St. Louis. He had been president of the Vaad Hoeir of St. Louis, the
founding president of Block Yeshiva
High School, a founding member of
Young Israel Synagogue of St. Louis, and
a former board member of the Jewish
Federation of St. Louis. Susman is survived by his wife, four children, and many
beloved grandchildren.
William Sawyer, MD 54
Sawyer, 82, died March 20, 2012.
He served nine years in the U.S. Army
followed by years of research and
teaching at Johns Hopkins University
School of Medicine, Mahidol University in
Bangkok, Thailand, and Indiana University
School of Medicine in Indianapolis. He was
dean of the medical school at Wright State
University in Dayton OH. He was president,
until his retirement in 1997, of the China
Medical Board of New York, a foundation
that supports research and education in
medicine, nursing and public health in
East and Southeast Asia. He was only the
second American to be awarded the China
Health Medal for his work in China. This
was presented in a ceremony in the
Great Hall of the People in Beijing. Sawyer
is survived by his wife, two children and
six grandchildren.
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Lois Gasteyer, NU 55
Gasteyer died Feb. 16, 2012, at age 77.
She was married to Theodore Hall
Gasteyer II, MD 57, for 54 years.
She was active in multiple community
organizations, including school PTAs and
the Christ Hospital Women’s Auxiliary.
She served on the Oak Lawn Library Board
and was instrumental in the establishment of the Oak Lawn Library Educational
Foundation. She is survived by her husband, two children and four grandchildren.
George Koehler, MD 58
Koehler died Jan. 24, 2012, at age 80. He
specialized in internal medicine and was
on the staff of St. Luke’s Hospital. He loved
playing golf and embraced the study of
the German language with a passion. He
is survived by his wife, two siblings, two
children and two grandchildren.

Faculty
Michael J. Welch, PhD
Welch, a pioneering radiochemist, died
May 6, 2012. He was 72. He joined the
Washington University faculty in 1967, and
was professor of radiology, of chemistry,
of biomedical engineering and of developmental biology. He was the founding
leader of the Oncologic Imaging Research
Program at the Alvin J. Siteman Cancer
Center at Barnes-Jewish Hospital and
Washington University School of Medicine
and a member of the cancer center’s
senior leadership. He was elected to the
Institute of Medicine and received many
of his field’s highest honors, including
the Benedict Cassen Award from the
Society of Nuclear Medicine. In 2008, the
society named its award for outstanding
contributions to radiopharmaceutical
research after Welch.

If you wish to make a tribute gift in honor
of any of the above alumni or faculty,
please contact: Pamela Buell, Washington
University Medical Alumni and Development,
Campus Box 1247, 7425 Forsyth Blvd., Suite 2100,
St. Louis MO 63105-2161, (314) 935-9691.
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Emeritus • 1953 • 1958 • 1963
• 1968 • 1973 • 1978 • 1983
• 1988 • 1993 • 1998 • 2003

Mark your calendar!
Make plans to return for the fun and
excitement of Reunion! Catch up with
classmates and learn what’s happening
at the School of Medicine.
Welcome reception

Class dinners and photos

CME programming

Activities around St. Louis

Dean’s luncheon

Reunion awards banquet

School updates and tours

And more fun!

Questions? Want to join your Reunion Committee?
medicalalumni@wustl.edu
314.935.9682 or 877.816.2586

April 25–28

REUNION
2013

Outlook 35

advancing health

Together
transforming lives
Leading together, the Washington University
community defines the forefront of medical innovation
— advancing human health, preparing tomorrow’s
leaders, and enriching the quality of life. A simple yet
significant way to support these efforts is by making
a planned gift through your will, trust, life insurance,
IRA, or qualified retirement plan.

Benefits can include:
n

Retaining control of assets during your lifetime
to provide for family and loved ones

n

Reducing estate taxes

n

Supporting scholarships, professorships, research,
and programs that are important to you

To learn how you can make a planned gift,
contact the Office of Planned Giving:
Poster session in the Farrell Learning and Teaching Center.

(800) 835-3503 or (314) 935-5373
plannedgiving.wustl.edu

Together, we can change lives!
For information on supporting the School of Medicine
through an outright gift, contact:
Pamela Buell, Associate Vice Chancellor for
Medical Alumni and Development
(314) 935-9698

email: meddev@wustl.edu
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Consult with your legal or tax advisor before making a charitable gift.

Transformation

Retectix LLC

Pipette tip packaging found new
meaning as sculpture created
by Material Monster, a student
group focused on materials reuse
and education. Caitlin E. Lee, an
undergraduate fine arts major
and founder of the group, and
Susan Q. Shen, a graduate student
in neuropathology, collaborated
with artist Catherine A. Leberg
and other Washington University
students in the effort. To learn
more, visit outlook.wustl.edu.
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Explore Outlook ONLINE
Musculoskeletal health

Reducing cancer in society

Nerve research benefits
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SEE MORE ONLINE
Related videos & content
Interactive learning tools
Archives & enhanced content

Understanding clinical studies
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Onsite emergency medicine
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